News | Ablation Systems | October 14, 2015

AtriCure Enters Into Definitive Agreement to Acquire nContact

Complementary product lines to provide additional solutions for serious forms of atrial fibrillation

AtriCure, definitive merger agreement, nContact Inc., atrial fibrillation solutions, cardiac ablation

October 14, 2015 — AtriCure Inc. announced it has entered into a definitive merger agreement under which AtriCure has agreed to acquire nContact Inc., a privately held developer of innovative cardiac ablation solutions.

The transaction consideration consists of an upfront payment of approximately 3.7 million shares of AtriCure common stock, valued at $24.60 per share, and approximately $8 million in cash, subject to closing adjustments. The transaction also includes up to $50 million in additional contingent consideration based on completion of enrollment of the CONVERGE IDE trial and PMA approval. Additionally, nContact shareholders are entitled to additional sales-based contingent consideration on revenue in excess of an annual growth rate of greater than 25 percent through 2019. All contingent consideration can be paid in either cash or AtriCure common stock, or a combination of both.

The transaction will combine two companies focused on treatment of the most serious forms of atrial fibrillation and is expected to:

  • Expand AtriCure’s addressable market;
  • Complement and expand AtriCure’s current product portfolio and minimally invasive (MIS) intellectual property portfolio;
  • Enhance AtriCure’s commitment to clinical science with the CONVERGE IDE clinical trial;
  • Accelerate and sustain AtriCure’s revenue growth rate; and
  • Drive continued margin expansion and operating leverage opportunities.

nContact, based in Morrisville, North Carolina, develops and markets a portfolio of innovative devices that provide for less invasive ablation options for the treatment of cardiac arrhythmias. The company’s technology is used in the Convergent procedure, a multidisciplinary therapy in which a closed-chest surgical epicardial ablation is performed, and then complemented by an endocardial catheter ablation performed by an electrophysiologist.

nContact is currently conducting the CONVERGE IDE clinical trial, the first head-to-head study to evaluate the Convergent procedure versus catheter ablation in patients with persistent Afib. In addition to the ongoing IDE trial, individual center results have been published in numerous peer reviewed papers.

Subject to customary closing conditions, the transaction is expected to close in the next several weeks. AtriCure shareholder approval is not required.

For more information: www.atricure.com

Related Content

News | Business| January 16, 2018
American College of Cardiology (ACC) Chief Executive Officer Shalom “Shal” Jacobovitz will be leaving the College...
CMS Launches New Voluntary Bundled Payments Model
News | Business| January 10, 2018
The Centers for Medicare & Medicaid Services (CMS) Center for Medicare and Medicaid Innovation (Innovation Center)...
Toshiba Medical Systems Changes Name to Canon Medical Systems Corp.
News | Business| January 08, 2018
January 8, 2018 — Canon Inc. and Canon Medical Systems Corp.
CMS Announces Final Changes, Cancellations of Mandatory Bundled Payment Models
News | Business| December 21, 2017
The Centers for Medicare & Medicaid Services (CMS) last week finalized the cancellation of the mandatory hip...
Catheter reprocessing can reduce costs in the cath and EP lab.
Feature | Business| December 19, 2017 | Lars Thording
As payers and other healthcare entities look to better manage costs, especially in the acute care setting, it is impo
FDA Issues Final Guidance on Investigational Device Exemption Categorization
News | Business| December 19, 2017
The U.S. Food and Drug Administration (FDA) recently issued a final guidance, “FDA Categorization of Investigational...
Congressional Budget Office Finds cutting ACA insurance mandate will cause 13 million people to become uninsured, higher insurance premiums. American Heart Association (AHA), #AHA2017
News | Business| December 06, 2017
December 6, 2017 — At the American Heart Association (AHA) annual meeting in November, a group of 16 non-partisan pat
5 Tips for Medical Device Engineers on FDA Design Controls
Feature | Business| November 24, 2017 | Jon Speer
If you are an engineer in the medical device industry, you probably have a love/hate relationship with the FDA-mandat
Videos | Business| November 09, 2017
A discussion with Peter L.
SCAI Successful in Securing Inpatient Status for AMI-PCI Patients
News | Business| November 09, 2017
In the Society for Cardiovascular Angiography and Interventions’ (SCAI) comment letter to the Centers for Medicare...
Overlay Init